Figure 1: Subject disposition. A total of 239 subjects were assessed for eligibility for the clinical trial. Of these, 134 (46%) were excluded, mostly due to fasting plasma glucose or HbA1c not being high enough. Of the 159 subjects who were eligible, 32, 63, 32, and 32 subjects were randomized into the placebo, 5mg, 10mg CCX140-B, and 30mg pioglitazone groups, respectively. Three subjects were excluded from the intent-to-treat population because of study medication being switched accidentally (1 each in the placebo and 10mg groups) and one subject who withdrew consent before receiving any study medication (pioglitazone group). There were 7 early withdrawals from the study, 3 in the 5mg CCX140-B group, and 2 each in the 10mg CCX140-B and pioglitazone groups. The two adverse events leading to withdrawal were one event of dyspepsia in the 5mg CCX140-B group and one event of gouty arthritis in the 10mg CCX140-B group.